Skip to main content

The Fundraising Ecosystem For Nordic Life Sciences And Raising Capital During Turbulent Times

LSX Nordic


Date: October 10, 2023

The Nordic region continues to be a beacon of innovation with private stage biotechs and startups continually raising capital, but in 2023 how are some of Europe’s leading investors viewing the field? This panel will discuss how investors are allocating their capital, hot trends to look out for, and how best private stage biotechs can utilise their capital efficiently as we head into 2024 and beyond. 

  1. How are investors viewing the field of the Nordic life sciences as an attractive region to invest in?
  2. What has got some of the leading investors in the space excited this year, and what are they going to be on the lookout in 2024?
  3. What have we learned in terms of navigating the private markets in 2023 and how can biotechs be best prepared for the future?


Professional Cropped Hicks William Mintz

William C. Hicks


William C. Hicks is Co-chair of the Life Sciences Practice Group at Mintz. He has extensive experience representing issuers, investors, and investment banks in structuring and executing IPOs, cross-over investments, alternative public offerings, including APOs, reverse mergers and Form 10 transactions, follow-on public offerings, CMPOs, registered directs, PIPEs, and private placements. His clients include hedge funds, venture capital firms, and private equity firms in customized investments in public companies, including structured PIPEs and registered directs. Bill also represents public companies in public and private financings, SEC compliance, corporate governance, and general counseling.

Sören Moller


Managing Partner, Novo Seeds

Charles Conn


Partner, Monograph Capital

Ingrid Teigland Akay


Managing Partner, Hadean Ventures

Claudio Costa


Operating Partner, Jeito Capital

Christina Takke


Managing Partner, V-Bio Ventures